Esophageal Cancer - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 591
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EF536FD5BCFEN
Leaflet:

Download PDF Leaflet

Esophageal Cancer - Pipeline Review, H2 2017
Esophageal Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2017, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.

Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 8, 41, 28, 1 and 15 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 4, 2 and 1 molecules, respectively.

Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Esophageal Cancer - Overview
Esophageal Cancer - Therapeutics Development
Esophageal Cancer - Therapeutics Assessment
Esophageal Cancer - Companies Involved in Therapeutics Development
Esophageal Cancer - Drug Profiles
Esophageal Cancer - Dormant Projects
Esophageal Cancer - Discontinued Products
Esophageal Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Esophageal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Companies, H2 2017 (Contd.4), H2 2017
Products under Development by Companies, H2 2017 (Contd.5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.3), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Esophageal Cancer - Pipeline by ADC Therapeutics Sarl, H2 2017
Esophageal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Esophageal Cancer - Pipeline by Almac Discovery Ltd, H2 2017
Esophageal Cancer - Pipeline by Ambrx Inc, H2 2017
Esophageal Cancer - Pipeline by Amgen Inc, H2 2017
Esophageal Cancer - Pipeline by Aprea AB, H2 2017
Esophageal Cancer - Pipeline by ArQule Inc, H2 2017
Esophageal Cancer - Pipeline by Array BioPharma Inc, H2 2017
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Esophageal Cancer - Pipeline by Bayer AG, H2 2017
Esophageal Cancer - Pipeline by BeiGene Ltd, H2 2017
Esophageal Cancer - Pipeline by BioStar Pharmaceuticals Inc, H2 2017
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Esophageal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Esophageal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Esophageal Cancer - Pipeline by Celgene Corp, H2 2017
Esophageal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Esophageal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Esophageal Cancer - Pipeline by Clovis Oncology Inc, H2 2017
Esophageal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017
Esophageal Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Eli Lilly and Co, H2 2017
Esophageal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Esophageal Cancer - Pipeline by Genmab A/S, H2 2017
Esophageal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Esophageal Cancer - Pipeline by Glycotope GmbH, H2 2017
Esophageal Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
Esophageal Cancer - Pipeline by Ignyta Inc, H2 2017
Esophageal Cancer - Pipeline by Immunocore Ltd, H2 2017
Esophageal Cancer - Pipeline by ImmunoFrontier Inc, H2 2017
Esophageal Cancer - Pipeline by Immunomedics Inc, H2 2017
Esophageal Cancer - Pipeline by Incyte Corp, H2 2017
Esophageal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Johnson & Johnson, H2 2017
Esophageal Cancer - Pipeline by Leap Therapeutics Inc, H2 2017
Esophageal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Esophageal Cancer - Pipeline by MaxiVAX SA, H2 2017
Esophageal Cancer - Pipeline by Mebiopharm Co Ltd, H2 2017
Esophageal Cancer - Pipeline by MedImmune LLC, H2 2017
Esophageal Cancer - Pipeline by Merck & Co Inc, H2 2017
Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Esophageal Cancer - Pipeline by Novartis AG, H2 2017
Esophageal Cancer - Pipeline by Omeros Corp, H2 2017
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc, H2 2017
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc, H2 2017
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Puma Biotechnology Inc, H2 2017
Esophageal Cancer - Pipeline by Rhizen Pharmaceuticals SA, H2 2017
Esophageal Cancer - Pipeline by Shionogi & Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
Esophageal Cancer - Pipeline by Steba Biotech SA, H2 2017
Esophageal Cancer - Pipeline by Stelic Institute & Co Inc, H2 2017
Esophageal Cancer - Pipeline by Supratek Pharma Inc, H2 2017
Esophageal Cancer - Pipeline by Symphogen A/S, H2 2017
Esophageal Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
Esophageal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Esophageal Cancer - Pipeline by Takara Bio Inc, H2 2017
Esophageal Cancer - Pipeline by Transgene Biotek Ltd, H2 2017
Esophageal Cancer - Pipeline by XuanZhu Pharma Co Ltd, H2 2017
Esophageal Cancer - Dormant Projects, H2 2017
Esophageal Cancer - Dormant Projects, H2 2017 (Contd.1), H2 2017
Esophageal Cancer - Dormant Projects, H2 2017 (Contd.2), H2 2017
Esophageal Cancer - Dormant Projects, H2 2017 (Contd.3), H2 2017
Esophageal Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Esophageal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Adaptimmune Therapeutics Plc
ADC Therapeutics Sarl
Aduro BioTech Inc
Advenchen Laboratories LLC
Almac Discovery Ltd
Ambrx Inc
Amgen Inc
Aprea AB
ArQule Inc
Array BioPharma Inc
Aslan Pharmaceuticals Pte Ltd
Bayer AG
BeiGene Ltd
BioStar Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cascadian Therapeutics Inc
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Clovis Oncology Inc
Cyclacel Pharmaceuticals Inc
DAE HWA Pharmaceutical Co Ltd
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Genmab A/S
GlaxoSmithKline Plc
Glycotope GmbH
Hanmi Pharmaceuticals Co Ltd
Hutchison MediPharma Ltd
Ignyta Inc
Immunocore Ltd
ImmunoFrontier Inc
Immunomedics Inc
Incyte Corp
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Leap Therapeutics Inc
Madrigal Pharmaceuticals Inc.
MaxiVAX SA
Mebiopharm Co Ltd
MedImmune LLC
Merck & Co Inc
Merrimack Pharmaceuticals Inc
Novartis AG
Omeros Corp
Omnitura Therapeutics Inc
Oncolys BioPharma Inc
Ono Pharmaceutical Co Ltd
Puma Biotechnology Inc
Rhizen Pharmaceuticals SA
Shionogi & Co Ltd
Spectrum Pharmaceuticals Inc
Steba Biotech SA
Stelic Institute & Co Inc
Supratek Pharma Inc
Symphogen A/S
Taiho Pharmaceutical Co Ltd
Taiwan Liposome Company Ltd
Takara Bio Inc
Transgene Biotek Ltd
XuanZhu Pharma Co Ltd
Skip to top


Esophageal Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Apr, 2017 · 493 pages
Endometrial Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 412 pages
Kidney Cancer - Pipeline Review, H1 2015 US$ 2,000.00 Jun, 2015 · 847 pages
Peritoneal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Oct, 2017 · 876 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages

Ask Your Question

Esophageal Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: